Drug
Etrasimod clinical trials
Also written APD334 and Velsipity.
- studies test it
- 23
- open now
- 4
- in phase 3
- 7
- first study started
- 2015
Keep track of what changes. Save the etrasimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 16
- Phase 3
- 7
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 3
Pfizer (11) · Arena Pharmaceuticals (8) · Everstar Therapeutics Limited (1) · Sir Run Run Shaw Hospital (1) · Maia Kayal (1) · Yale University (1)
Studies
Open first, then newest update. How each study uses etrasimod is read from its arms, and is right about nine times in ten.
Testing it · 23
- Etrasimod as Prevention of PouchitisRecruitingPhase 2Maia KayalNCT07486921Written as etrasimod
- Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCNot yet recruitingPhase 4Sir Run Run Shaw HospitalNCT07782242Written as Etrasimod
- A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingPhase 2PfizerNCT07470879Written as Etrasimod
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingPhase 2PfizerNCT05287126Written as Etrasimod
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3PfizerNCT03950232Written as Etrasimod
- A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenCompletedPhase 1PfizerNCT07153159Written as Etrasimod
- A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseTerminatedPhase 2/3PfizerNCT04173273Written as Etrasimod
- Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisWithdrawnPhase 2Yale UniversityNCT06521762Written as Etrasimod
- Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisCompletedPhase 2PfizerNCT04607837Written as Etrasimod
- A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by InjectionTerminatedPhase 2/3PfizerNCT05732454Written as etrasimod
- Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2PfizerNCT05061446Written as Etrasimod
- Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia AreataCompletedPhase 2PfizerNCT04556734Written as Etrasimod
- A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic EsophagitisCompletedPhase 2PfizerNCT04682639Written as Etrasimod
- A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Everstar Therapeutics LimitedNCT04176588Written as Etrasimod
- Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)CompletedPhase 3PfizerNCT04706793Written as Etrasimod
- Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Arena PharmaceuticalsNCT03996369Written as Etrasimod
- Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Arena PharmaceuticalsNCT03945188Written as Etrasimod
- A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Arena PharmaceuticalsNCT04162769Written as Etrasimod 1 mg
- Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary CholangitisTerminatedPhase 2Arena PharmaceuticalsNCT03155932Written as APD334
- Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Arena PharmaceuticalsNCT02536404Written as Etrasimod
Codes
What other systems call etrasimod · ClinicalTrials.gg INT001238
- MeSH (NLM) C000656249etrasimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6WH8495MMHETRASIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q27265630etrasimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166965EtrasimodOne source FDA
- DrugBank DB14766One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656249 | etrasimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6WH8495MMH | ETRASIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27265630 | etrasimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166965 | Etrasimod | One source FDA |
| DrugBank | DB14766 | — | One source Wikidata |
Also registered as etrasimod arginine (UNII MXE5EMA09L).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.